Using Interleukin-2 to Treat Metastatic Melanoma
Author Information
Author(s): Petrella T., Quirt I., Verma S., Haynes A.E., Charette M., Bak K.
Primary Institution: Cancer Care Ontario’s Program in Evidence-Based Care
Hypothesis
What is the role of single-agent interleukin-2 (il-2) in the treatment of adults with metastatic melanoma?
Conclusion
High-dose interleukin-2 can produce durable complete remissions in a select group of patients with metastatic melanoma.
Supporting Evidence
- High-dose interleukin-2 has response rates similar to standard chemotherapy.
- Patients with non-visceral metastases and fewer metastatic sites have a much higher response rate.
- The treatment is recommended for patients with good performance status and specific metastatic conditions.
Takeaway
Interleukin-2 is a treatment that can help some patients with advanced skin cancer feel better for a long time, but it only works for certain people.
Methodology
A systematic review was conducted, and clinical recommendations were drafted based on the evidence and feedback from practitioners.
Potential Biases
The recommendations may be influenced by the limited availability of phase III data.
Limitations
The lack of large randomized trials comparing il-2 to standard treatments means recommendations are based largely on phase II data.
Participant Demographics
Patients with good performance status and specific metastatic conditions were considered for treatment.
Want to read the original?
Access the complete publication on the publisher's website